LAB — Standard BioTools Share News
0.000.00%
Last trade - 00:00- $258.47m
- -$217.95m
- $85.33m
Brief: Fluidigm Announces Collaboration Agreement With The Abu Dhabi Stem Cells Center
Brief: Fluidigm Files Preliminary Proxy Statement
Fluidigm Corp expected to post a loss of 28 cents a share - Earnings Preview
Brief: Fluidigm Announces Preliminary Revenue Exceeding Guidance For The Fourth Quarter And Full Year 2021
Brief: Fluidigm Confirms Advanta Dx SARS-Cov-2 RT-PCR Assay On The Company’s Biomark Platform Detects Omicron Variant Of Covid-19
Brief: Neuberger Berman Group Says Believe Fluidigm Has Potential For Growth As Stand-Alone Publicly Traded Co
Fluidigm Corp reports results for the quarter ended in September - Earnings Summary
Brief: Fluidigm Corp - Undertaking A Review Of Various Options, Including With Regard To Strategic Alternatives
Marketing Program In Collaboration With Visiopharm
Brief: Fluidigm Collaborates With Karolinska Institutet To Accelerate Customer Adoption Of New CyTOF XT
Brief: CyTOF And Maxpar Direct Technologies Used In Study On Pregnant Women With SARS-CoV-2
Fluidigm Corp reports results for the quarter ended in June - Earnings Summary
Brief: Fluidigm Announces Second Quarter 2021 Financial Results
Marketing Agreement With ImaBiotech
Marketing Agreement With Ultivue For Biomarker Imaging Solutions For Precision Medicine
Fluidigm Corp expected to post a loss of 19 cents a share - Earnings Preview
Media: Medical technology firm Fluidigm is said to explore sale - Bloomberg News
Brief: Rover Labs Provides Saliva-Based Covid-19 Testing To New York City Public Schools
Fluidigm: Rises after hedge fun Caligan takes 11% stake